- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
GE HealthCare Debuts New PET/MRI System at SNMMI Conference
The newly launched Signa PET/MR Air device offers technological features that may bolster image quality and enhance diagnostic accuracy for diseases such as prostate cancer and Alzheimer’s disease.
Offering a variety of reported technological advances to facilitate the diagnosis of conditions such as Alzheimer’s disease and prostate cancer, the Signa PET/MR Air system (GE HealthCare) will be launched at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago.
The Signa PET/MR Air system combines the high sensitivity of positron emission tomography (PET) with the anatomical precision offered by magnetic resonance imaging (MRI) in one device, according to GE HealthCare. The company said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the Signa PET/MR Air system may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases.
GE HealthCare said integrating prostate-specific membrane antigen (PSMA)-targeted PET radiotracer agents with the newly launched Signa PET/MR Air system (shown above) may help optimize staging and facilitate a more precise diagnosis in prostate cancer cases. (Image courtesy of GE HealthCare)
Other features of the Signa PET/MR Air system include the Time-of-Flight (TOF) PET detector and MotionFree Brain PET. Addressing patient motion during exams without external tracking devices, MotionFree Brain PET enables consistent image quality, which reduces repeat scans and may potentially improve diagnostic accuracy for challenging patients, according to the company. GE HealthCare added that the sensitivity of the ToF PET detector can detect adverse effects in a single scan and provide insights into disease progression.
“Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring,” noted Jie Xue, president and CEO of MR at GE HealthCare. “We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
SNMMI: Can Ultra-Low Dose PET Supplant the Need for CT Attenuation Correction?
June 11th 2024Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.
SNMMI: AI May Enhance Detection and Risk Assessment for Multiple Cancers on Whole-Body PET/CT Scans
June 10th 2024Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.
